Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinisches Magazin
Erschienen in:

01.02.2015 | Radiologie

Re-Staging solider Tumoren

Der Radiologe als Entscheidungsträger: Neue Möglichkeiten im Follow-up

verfasst von: A.o. Univ.-Prof. Dr. Helmut Schöllnast

Erschienen in: Wiener klinisches Magazin | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Radiologische Verfahren wie die Computertomographie (CT) und die Magnetresonanztomographie (MRT) stellen wichtige Werkzeuge in der Beurteilung eines Ansprechens maligner Tumoren auf systemische oder lokale Therapien dar. Klassische radiologische Beurteilungsmethoden ziehen als Kriterium für ein Therapieansprechen bzw. Therapieversagen Änderungen in der Tumorgröße heran. Eine Verkleinerung des Tumors kann jedoch, insbesondere bei Anwendung zielgerichteter Therapien, trotz Ansprechen auf die Therapie verzögert auftreten. Als Konsequenz wurden Kriterien entwickelt, die neben der Tumorgröße auch die Dichte des Tumors bzw. die Kontrastmittelaufnahme als Kriterium eines Ansprechens bzw. eines Therapieversagens einbeziehen. Neben diesen etablierten Verfahren zur Beurteilung eines Therapieansprechens gewinnen funktionelle radiologische Verfahren zunehmend an Interesse. Zu diesen sowohl qualitativen als auch quantitativen Verfahren zählen vor allem Perfusionsmessungen mittels CT und MRT (CT-Perfusion, MR-Perfusion) und Diffusionsmessungen mittels MRT (diffusionsgewichtete MRT). Dieser Artikel gibt einen Überblick über die Wertigkeit und die Limitationen dieser funktionellen Verfahren in der Beurteilung des Therapieansprechens von Tumoren.
Vorheriger Artikel Klassische Muster pulmonaler Fibrosen
Literatur
1.
Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K (2013) Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 33:1323–1341CrossRefPubMed
2.
Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582CrossRefPubMed
3.
Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF (2003) Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol 58:311–314CrossRefPubMed
4.
Rothe JH, Grieser C, Lehmkuhl L et al (2013) Size determination and response assessment of liver metastases with computed tomography – comparison of RECIST and volumetric algorithms. Eur J Radiol 82:1831–1839CrossRefPubMed
5.
Uhl M, Saueressig U, van Buiren M et al (2006) Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618–623CrossRefPubMed
6.
Lee SC, Poptani H, Pickup S et al. (2010) Early detection of radiation therapy response in non-Hodgkin’s lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 23:624–632CrossRefPubMed
7.
de Lussanet QG, Backes WH, Griffioen AW et al (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63:1309–1315CrossRefPubMed
8.
Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572–4578CrossRefPubMedCentralPubMed
9.
Thukral A, Thomasson DM, Chow CK et al (2007) Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab – initial experience. Radiology 244:727–735CrossRefPubMed
10.
Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A (2007) CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244:486–493CrossRefPubMed
11.
Pandharipande PV, Krinsky GA, Rusinek H, Lee VS (2005) Perfusion imaging of the liver: current challenges and future goals. Radiology 234:661–673CrossRefPubMed
12.
Kiessling F, Boese J, Corvinus C et al (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14:1226–1233PubMed
13.
Gandhi D, Chepeha DB, Miller T et al (2006) Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 27:101–106PubMed
14.
Li SP, Padhani AR (2012) Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35:745–763CrossRefPubMed
15.
Sahani DV, Kalva SP, Hamberg LM et al (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234:785–792CrossRefPubMed
16.
Zhang Q, Yuan ZG, Wang DQ, Yan ZH, Tang J, Liu ZQ (2010) Perfusion CT findings in liver of patients with tumor during chemotherapy. World J Gastroenterol 16:3202–3205CrossRefPubMedCentralPubMed
17.
Falk SJ, Ramsay JR, Ward R, Miles K, Dixon AK, Bleehen NM (1994) BW12C perturbs normal and tumour tissue oxygenation and blood flow in man. Radiother Oncol 32:210–217CrossRefPubMed
18.
Faria SC, Ng CS, Hess KR et al (2007) CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol 189:378–385CrossRefPubMed
19.
Fournier LS, Oudard S, Thiam R et al (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256:511–518CrossRefPubMed
20.
Koukourakis MI, Mavanis I, Kouklakis G et al (2007) Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 30:315–318CrossRefPubMed
21.
Lind JS, Meijerink MR, Dingemans AM et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20:2890–2898CrossRefPubMedCentralPubMed
22.
McNeel DG, Eickhoff J, Lee FT et al (2005) Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851–7860CrossRefPubMed
23.
Meijerink MR, van Cruijsen H, Hoekman K et al (2007) The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17:1700–1713CrossRefPubMed
24.
Ng CS, Charnsangavej C, Wei W, Yao JC (2011) Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 196:569–576CrossRefPubMed
25.
Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM (2010) Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol 194:166–171CrossRefPubMed
26.
Ng QS, Goh V, Carnell D et al (2007) Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67:1375–1380CrossRefPubMed
27.
Ng QS, Goh V, Milner J, Padhani AR, Saunders MI, Hoskin PJ (2007) Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: in vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys 67:417–424CrossRefPubMed
28.
Petralia G, Preda L, Giugliano G et al (2009) Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume. J Comput Assist Tomogr 33:552–559CrossRefPubMed
29.
Schlemmer M, Sourbron SP, Schinwald N et al (2011) Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Radiol 77:312–318CrossRefPubMed
30.
Thomas JP, Arzoomanian RZ, Alberti D et al (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223–231CrossRefPubMed
31.
Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147CrossRefPubMedCentralPubMed
32.
Xiong HQ, Herbst R, Faria SC et al (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22:459–466CrossRefPubMed
33.
Han KS, Jung DC, Choi HJ et al (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 116:2332–2342PubMed
34.
Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P (2003) Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 57:1351–1356CrossRefPubMed
35.
van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E (2010) Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 5:95–112CrossRefPubMedCentralPubMed
36.
Wang J, Wu N, Cham MD, Song Y (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090–1096CrossRefPubMed
37.
38.
Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185–188CrossRefPubMed
39.
Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210–221CrossRefPubMed
40.
Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76(1):36–42CrossRef
41.
42.
Hayano K, Shuto K, Koda K, Yanagawa N, Okazumi S, Matsubara H (2009) Quantitative measurement of blood flow using perfusion CT for assessing clinicopathologic features and prognosis in patients with rectal cancer. Dis Colon Rectum 52:1624–1629CrossRefPubMed
43.
Goh V, Halligan S, Wellsted DM, Bartram CI (2009) Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 19:79–89CrossRefPubMed
44.
Garcia-Figueiras R, Goh VJ, Padhani AR et al (2013) CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 200:8–19CrossRefPubMed
45.
Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900CrossRefPubMed
46.
Koh DM, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738CrossRefPubMed
47.
Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837CrossRefPubMedCentralPubMed
48.
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250:466–473CrossRefPubMed
49.
Jain R, Scarpace LM, Ellika S et al (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96:423–431CrossRefPubMed
50.
Hein PA, Kremser C, Judmaier W et al (2003) Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 45:214–222CrossRefPubMed
51.
Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843–847CrossRefPubMed
52.
Sun YS, Zhang XP, Tang L et al (2010) Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 254:170–178CrossRefPubMed
53.
Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554CrossRefPubMed
54.
Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102:5524–5529CrossRefPubMedCentralPubMed
55.
Koh DM, Scurr E, Collins D et al (2007) Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 188:1001–1008CrossRefPubMed
56.
Dzik-Jurasz A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307–308CrossRefPubMed
57.
DeVries AF, Kremser C, Hein PA et al (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56:958–965CrossRefPubMed
58.
Goh V, Bartram C, Halligan S (2009) Effect of intravenous contrast agent volume on colorectal cancer vascular parameters as measured by perfusion computed tomography. Clin Radiol 64:368–372CrossRefPubMed
59.
Goh V, Liaw J, Bartram CI, Halligan S (2008) Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. AJR Am J Roentgenol 191:W288–292CrossRef
60.
Goh V, Halligan S, Bartram CI (2007) Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? Radiology 242:777–782CrossRefPubMed
61.
Goh V, Shastry M, Engledow A et al (2011) Commercial software upgrades may significantly alter perfusion CT parameter values in colorectal cancer. Eur Radiol 21:744–749CrossRefPubMed
62.
Braithwaite AC, Dale BM, Boll DT, Merkle EM (2009) Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 250:459–465CrossRefPubMed
63.
Kim SY, Lee SS, Byun JH et al (2010) Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 255:815–823CrossRefPubMed
64.
Kwee TC, Takahara T, Koh DM, Nievelstein RA, Luijten PR (2008) Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 28:1141–1148CrossRefPubMed
Metadaten
Titel
Re-Staging solider Tumoren
Der Radiologe als Entscheidungsträger: Neue Möglichkeiten im Follow-up
verfasst von
A.o. Univ.-Prof. Dr. Helmut Schöllnast
Publikationsdatum
01.02.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 1/2015
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-014-0025-2

Weitere Artikel der Ausgabe 1/2015

Antiinfektive Erstherapie bei Sepsis

  • Leitthema

Erste Daten wirken vielversprechend

  • aktuell

Klassische Muster pulmonaler Fibrosen

  • Radiologie

Letzte Wirklichkeit

  • Editorial

Intensivmedizinisches Management vor und nach Lebertransplantation

  • Intensivmedizin

Panorama

  • Panorama